Ander Vergara
Overview
Explore the profile of Ander Vergara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martos-Guillami N, Vergara A, Llorens-Cebria C, Motto A, Martinez-Diaz I, Goncalves F, et al.
Front Pharmacol
. 2024 Oct;
15:1415879.
PMID: 39434906
Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not...
2.
Toapanta N, Sanchez-Gavilan E, Guirao C, Leon Roman J, Ramos N, Vergara A, et al.
Nefrologia (Engl Ed)
. 2024 Jul;
44(4):519-526.
PMID: 39013756
Introduction: Diabetic Kidney Disease (DKD) is the most common cause of end-stage chronic kidney disease (CKD), conditioning these patients to a worse renal prognosis and higher cardiovascular mortality and/or requirement...
3.
Sun Q, Wagg C, Guven B, Wei K, de Oliveira A, Silver H, et al.
Basic Res Cardiol
. 2023 Dec;
119(1):133-150.
PMID: 38148348
Heart failure is a prevalent disease worldwide. While it is well accepted that heart failure involves changes in myocardial energetics, what alterations that occur in fatty acid oxidation and glucose...
4.
Zamora J, Lopez-Martinez M, Liebana M, Leon Roman J, Bermejo S, Vergara A, et al.
J Clin Med
. 2023 Mar;
12(6).
PMID: 36983419
Background: Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to...
5.
Martinez-Diaz I, Martos N, Llorens-Cebria C, Alvarez F, Bedard P, Vergara A, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834836
Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin...
6.
Vergara A, Wang K, Colombo D, Gheblawi M, Rasmuson J, Mandal R, et al.
Clin Kidney J
. 2023 Feb;
16(2):272-284.
PMID: 36751625
Background: Angiotensin-converting enzyme 2 (ACE2), the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly expressed in the kidneys. Beyond serving as a crucial endogenous regulator of the...
7.
Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, et al.
Transpl Int
. 2023 Jan;
35:11073.
PMID: 36685666
[This corrects the article DOI: 10.3389/ti.2022.10693.].
8.
Vergara A, Llorens-Cebria C, Martos N, Martinez-Diaz I, Stein F, Dominguez-Baez P, et al.
Clin Sci (Lond)
. 2022 Dec;
137(1):87-104.
PMID: 36524468
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to delay diabetic kidney disease (DKD) progression on top of the standard of care with the renin-angiotensin system (RAS) blockade. The molecular mechanisms...
9.
Vergara A, Jacobs-Cacha C, Llorens-Cebria C, Ortiz A, Martinez-Diaz I, Martos N, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361612
Treatments with sodium-glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination...
10.
Lopez-Martinez M, Torres I, Bermejo S, Moreso F, Garcia-Carro C, Vergara A, et al.
Transpl Int
. 2022 Oct;
35:10693.
PMID: 36311259
No abstract available.